Skip to main content

Advertisement

SpringerLink
Log in

Aging and HIV Infection

  • HIV Perspectives After 25 Years
  • Published:
Journal of Urban Health Aims and scope Submit manuscript

Abstract

With the advent of highly active antiretroviral therapy (HAART) in mid-1995, the prognosis for HIV-infected individuals has brightened dramatically. However, the conjunction of potent antiviral therapy and longer life expectancy may engender a variety of health risks that, heretofore, HIV specialists have not had to confront. The long-term effects of HIV infection itself and exposure to antiretroviral agents is unknown. Several aspects of aging, including psychiatric disease, neurocognitive impairment, and metabolic and hormonal disorders, may be influenced by chronic exposure to HIV and/or HIV therapeutics. In this paper, we discuss the health issues confronting HIV-infected older adults and areas for future research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.

    Article  PubMed  Google Scholar 

  2. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933–1942.

    Article  PubMed  CAS  Google Scholar 

  3. Mack KA, Ory MG. AIDS and older Americans at the end of the twentieth century. J Acquir Immune Defic Syndr. 2003;33:S68–S75.

    PubMed  Google Scholar 

  4. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2003(Vol. 15). Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2004. Also available at: http://www.cdc.gov/hiv/stats/hasrlink.htm.

  5. Casau NC. Perspective on HIV infection and aging: emerging research on the horizon. Clin Infect Dis. 2005;41:855–863.

    Article  PubMed  Google Scholar 

  6. El-Sadr W, Gettler J. Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med. 1995;155:184–186.

    Article  PubMed  CAS  Google Scholar 

  7. Chiao EY, Ries KM, Sande MA. AIDS and the elderly. Clin Infect Dis. 1999;28:740–745.

    Article  PubMed  CAS  Google Scholar 

  8. Feldman MD. Sex, AIDS, and the elderly. Arch Intern Med. 1994;154:19–20.

    Article  PubMed  CAS  Google Scholar 

  9. Gfroerer J, Penne M, Pemberton M, Folsom R. Substance abuse treatment need among older adults in 2020: the impact of the aging baby-boom cohort. Drug Alcohol Depend. 2003;69;127–135.

    Article  PubMed  Google Scholar 

  10. Schable B, Chu SY, Diaz T. Characteristics of women 50 years of age or older with heterosexually acquired AIDS. Am J Public Health. 1996;86:1616–1618.

    Article  PubMed  CAS  Google Scholar 

  11. Stall R, Catania J. AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med. 1994;154:57–63.

    Article  PubMed  CAS  Google Scholar 

  12. Zingmond DS, Kilbourne AM, Justice AC, et al. Differences in symptom expression in older HIV-positive patients: The Veterans Aging Cohort 3 Site Study and HIV Cost andService Utilization Study experience. J Acquir Immune Defic Syndr. 2003;33:S84–S92.

    PubMed  Google Scholar 

  13. Savasta AM. HIV: associated transmission risks in older adults—an integrative review of the literature. J Assoc Nurses AIDS Care. 2004;15:50–59.

    Article  PubMed  Google Scholar 

  14. Centers for Disease Control and Prevention. HIV diagnoses among injection drug users in states with HIV surveillance—25 states, 1994–2000. MMWR Morb Mortal Wkly Rep. 2003;52(27):634–636.

    Google Scholar 

  15. Shah SS, Mcgowan JP, Smith C, Blum S, Klein RS. Comorbid conditions, treatment and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis. 2002;35:1238–1243.

    Article  PubMed  Google Scholar 

  16. Kwiatkowski CF, Booth RE. HIV risk behaviors among older American drug users. J Acquir Immune Defic Syndr. 2003;33:S131–S137.

    PubMed  Google Scholar 

  17. Lekas HM, Schrimshaw EW, Siegel K. Pathways to HIV testing among adults aged fifty and older with HIV/AIDS. AIDS Care. 2005;17:674–687.

    Article  PubMed  Google Scholar 

  18. National Institute on Drug Abuse. Research Report Series: Heroin Abuse and Addiction. April 2000. Available at: http://www.nida.nih.gov. Accessed March, 2005.

  19. Justice AC, McGinnis KA, Atkinson JH, et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS. 2004;18:S49–S59.

    Article  PubMed  Google Scholar 

  20. Weintraub E, Weintraub D, Dixon L, et al. Geriatric patients on a substance abuse consultation service. Am J Geriatr Psychiatry. 2002;10(3):337–342.

    Article  PubMed  Google Scholar 

  21. Arndt S, Turvey CL, Flaum M. Older offenders, substance abuse, and treatment. Am J Geriatr Psychiatry. 2002;10(6):733–739.

    Article  PubMed  Google Scholar 

  22. Anderson TL, Levy JA. Marginality among older injectors in today’s illicit drug culture: assessing the impact of ageing. Addiction. 2003;98:761–770.

    Article  PubMed  Google Scholar 

  23. Prins M, Hernandez A, I, Brettle RP, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS. 1997;11:1747–1756.

    Article  PubMed  CAS  Google Scholar 

  24. Tyndall MW, Craib KJ, Currie S, Li K, O’Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr. 2001;28:351–357.

    PubMed  CAS  Google Scholar 

  25. Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;41:864–872.

    Article  PubMed  Google Scholar 

  26. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–728.

    Article  PubMed  CAS  Google Scholar 

  27. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–381.

    Article  PubMed  Google Scholar 

  28. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002;113:91–98.

    Article  PubMed  Google Scholar 

  29. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology. 1992;42:1472–1476.

    PubMed  CAS  Google Scholar 

  30. Chiesi A, Vella S, Dally LG, et al. Epidemiology of AIDS dementia complex in Europe. J Acquir Immune Defic Syndr. 1996;11:39–44.

    CAS  Google Scholar 

  31. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology. 2004;63:822–827.

    PubMed  CAS  Google Scholar 

  32. Schoenbaum EE, Hartel D, Lo Y, et al. HIV infection, drug use and onset of natural menopause. Clin Infect Dis. 2005;41:1517–1524.

    Article  PubMed  Google Scholar 

  33. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. J AIDS. 2003;17:1917–1923.

    Article  Google Scholar 

  34. Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis. 2005;41:1794–1803.

    Article  PubMed  CAS  Google Scholar 

  35. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.

    Article  PubMed  Google Scholar 

  36. Brown TT, Li X, Cole SR. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort study. AIDS. 2005;19:1375–1383.

    Article  PubMed  CAS  Google Scholar 

  37. Howard AA, Floris-Moore M, Arnsten JH, et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis. 2005;40:1492–1499.

    Article  PubMed  CAS  Google Scholar 

  38. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–1184.

    Article  PubMed  Google Scholar 

  39. Dobs A, Brown T. Metabolic abnormalities in HIV disease and injection drug use. J Acquir Immune Defic Syndr. 2002;31:S70–S77.

    PubMed  CAS  Google Scholar 

  40. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38:426–431.

    Article  PubMed  CAS  Google Scholar 

  41. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482–490.

    Article  PubMed  Google Scholar 

  42. Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis. 2003;37:S132–S136.

    Article  PubMed  CAS  Google Scholar 

  43. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63–F67.

    Article  PubMed  CAS  Google Scholar 

  44. Arnsten JH, Freeman R, Santoro N, Schoenbaum EE. HIV infection and protease inhibitor use are not associated with reduced bone mineral density in older HIV-infected women [Abstr 103]. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA.

  45. Nolan D, Upton R, McKinnon E. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275–1280.

    Article  PubMed  CAS  Google Scholar 

  46. Vescini F, Borderi M, Buffa A, Sinicropi G, Tampellini L, Chiodo F, et al. Bone mass in HIV-infected patients: focus on the role of therapy and sex. J Acquir Immune Defic Syndr. 2003;33:405–407.

    PubMed  Google Scholar 

  47. McGowan I, Cheng A, Coleman S, et al. Assessment of bone mineral density (BMD) in HIV-infected antiretroviral-therapy-naïve patients [abstract 628]. Presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago.

  48. Clark RA, Cohn SE, Jarek C, et al. Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic Syndr. 2000;23:99–100.

    PubMed  CAS  Google Scholar 

  49. McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med. 1985;103:350–356.

    PubMed  CAS  Google Scholar 

  50. Brambilla DJ, McKinlay SM. A prospective study of factors affecting age at menopause. J Clin Epidemiol. 1989;42:1031–1039.

    Article  PubMed  CAS  Google Scholar 

  51. Clark RA, Bessinger R. Clinical manifestations and predictors of survival in older women infected with HIV. J Acquir Immune Defic Syndr. 1997;15:341–345.

    CAS  Google Scholar 

  52. Torgerson DJ, Avenell A, Russell IT, Reid DM. Factors associated with onset of menopause in women aged 45–49. Maturitas. 1994;19:83–92.

    Article  PubMed  CAS  Google Scholar 

  53. Miller SA, Santoro N, Lo Y, et al. Menopause symptoms in HIV-infected and drug-using women. Menopause. 2005;12:348–356.

    Article  PubMed  Google Scholar 

  54. Clay PG, Lam AI. Testosterone replacement therapy for bone loss prevention in HIV-infected males. Ann Pharmacother. 2003 Apr;37(4):582–585.

    Article  PubMed  CAS  Google Scholar 

  55. Siegel K. Strategies for coping with fatigue among HIV-positive individuals fifty years and older. AIDS Patient Care STDs. 2004;18:275–288.

    Article  PubMed  Google Scholar 

  56. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis. Nov 2002;2(11):692–699.

    Article  PubMed  CAS  Google Scholar 

  57. Purcell DW, Wolitski RJ, Hoff CC, Parsons JT, Woods WJ, Halkitis PN. Predictors of the use of Viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men. AIDS. 2005 Apr;19(Suppl 1):S57–S66.

    Article  PubMed  CAS  Google Scholar 

  58. Moyle GJ, Schoelles K, Fahrbach K, Frame D, James K, Scheye R, Cure-Bolt N. Efficacy of Selected Treatments of HIV Wasting: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr. 2004 Dec 1;(37):S262–S276.

    Google Scholar 

  59. Choi HH, Gray PB, Storer TW, Calof OM, Woodhouse L, Singh AB, et al. Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. J Clin Endocrinol Metab. 2005 Mar;90(3):1531–1541.

    Article  PubMed  CAS  Google Scholar 

  60. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol. 2004 Aug;24(4):379–385.

    Article  PubMed  CAS  Google Scholar 

  61. Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J, Dzekov C, Sinha-Hikim I, Bhasin S. Dose-dependent effects of testosterone on sexual function, mood and visuospatial cognition in older men. J Clin Endocrinol Metab. 2005 Apr 12; [Epub ahead of print] First published April 12, 2005 as doi:10.1210/jc.2005–0247.

  62. Bhasin S. Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression. Clin Infect Dis. 2003;37:S142–S149.

    Article  PubMed  CAS  Google Scholar 

  63. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298–302.

    Article  PubMed  CAS  Google Scholar 

  64. Lo JC, Kazemi MR, Hsue PY, et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis. 2005;41:1335–1340.

    Article  PubMed  CAS  Google Scholar 

  65. Hadigan C, Corcoran C, Stanley, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab. 2000;85:35–41.

    Article  PubMed  CAS  Google Scholar 

  66. Hadigan C. Insulin resistance among HIV-infected patients: unraveling the mechanism. Clin Infect Dis. 2005;41:1341–1342.

    Article  PubMed  Google Scholar 

  67. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251–20254.

    Article  PubMed  CAS  Google Scholar 

  68. Petit JM, Duong M, Duvillard, et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Horm Metab Res. 2000;32:367–372.

    PubMed  CAS  Google Scholar 

  69. Passariello N, Guiugliano D, Ceriello A, Chiariello A, Sgambato S, D’Onofrio F. Impaired insulin response to glucose but not to arginine in heroin addicts. J Endocrinol Invest. 1986;9:353–357.

    PubMed  CAS  Google Scholar 

  70. Ceriello A, Giugliano D, Passariello N, et al. Impaired glucose metabolism in heroin and methadone users. Horm Metab Res. 1987;19:430–433.

    PubMed  CAS  Google Scholar 

  71. Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis. 2003;36:1318–1323.

    Article  PubMed  Google Scholar 

  72. Hadigan C, Corcoran C, Basgoz N. Metformin in the treatment of HIV lipodystrophy syndrome. JAMA. 2000;284:472–477.

    Article  PubMed  CAS  Google Scholar 

  73. van Wijk JP, de Koning EJ, Cabezas M, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy. Ann Intern Med. 2005;143:337–346.

    PubMed  Google Scholar 

  74. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978–2982.

    Article  PubMed  CAS  Google Scholar 

  75. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056–1074.

    Article  PubMed  CAS  Google Scholar 

  76. Maccari S, Bassi C, Zanoni P, Plancher AC. Plasma cholesterol and triglycerides in heroin addicts. Drug Alcohol Depend. 1991;29:183–187.

    Article  PubMed  CAS  Google Scholar 

  77. Martin LD, Vandhuick O, Guillo P, et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis. 2005; Aug 29 [Epub ahead of print].

  78. Passalaris JD, Sepkowtiz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis. 2000;31:787–797.

    Article  PubMed  CAS  Google Scholar 

  79. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther. 2003 May;17(3):265–285.

    Article  PubMed  CAS  Google Scholar 

  80. Manfredi R. HIV disease and advanced age: an increasing therapeutic challenge. Drugs Aging. 2002;19(9):647–669.

    Article  PubMed  CAS  Google Scholar 

  81. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and complicated agents. Clin Pharmacokinet. 2003;42(3):223–282.

    Article  PubMed  Google Scholar 

  82. Knobel H, Guelar A, Valldecillo G, et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS. 2001;15:1591–1593.

    Article  PubMed  CAS  Google Scholar 

  83. Gourevitch MN. Interactions between HIV-related medications and methadone: an overview. Mt Sinai J Med. 2001;68:227–228.

    PubMed  CAS  Google Scholar 

  84. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother. 2002;10:1598–1613.

    Article  Google Scholar 

  85. Kresina TF, Flexner CW, Sinclair J, Correia MA, Stapleton JT, Adeniyi-Jones S, Cargill V, Cheever LW. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retrovir. 2002;18:757–770.

    Article  PubMed  Google Scholar 

  86. Fulk LJ, Kane BE, Phillips KD, Bopp CM, Hand GA. Depression in HIV-infected patients: allopathic, complementary, and alternative treatments. J Psychosom Res. 2004 Oct;57(4):339–351.

    PubMed  CAS  Google Scholar 

  87. Hsiao AI, Wong MD, Kanouse DE, et al. Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:157–165.

    Article  PubMed  Google Scholar 

  88. Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf. 2004;27:773–797.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Data in this manuscript were collected by the Women’s Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases with supplemental funding from the National Cancer Institute, the National Institute on Drug Abuse (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590). Data were also included from the Natural History of HIV Infection in Intravenous Drug Users (R01DA04347–PI Ellie E Schoenbaum), Natural History of Menopause in HIV-Infected Drug Users (R01DA0135–PI Ellie E Schoenbaum), Atherosclerosis, Bone Loss, Drug Use, and HIV in Older Men (R01DA014998–PI Robert S Klein) all funded by the National Institute on Drug Abuse. Funding is also provided by the National Institute of Child Health and Human Development (UO1-CH-32632) the National Center for Research Resources (MO1-RR-00071, MO1-RR-00079, MO1-RR-00083).

Author information

Authors and Affiliations

  1. Division of Geographic Medicine and Infectious Disease, Department of Medicine, Tufts-New England Medical Center, 750 Washington Street #41, Boston, MA, 02111, USA

    Rakhi Kohli MD, MS

Authors
  1. Rakhi Kohli MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert S. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ellie E. Schoenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kathryn Anastos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Howard Minkoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Henry S. Sacks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rakhi Kohli MD, MS.

Additional information

Dr. Klein and Dr. Schoenbaun are with the Division of Infectious Diseases, Department of Medicine and The AIDS Research Program, Department of Epidemiology and Population Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Dr. Anastos is with the Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Dr. Minkoff is with the Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY; Dr. Sacks is with the Department of Community and Preventive Medicine, Mount Sinai School of Medicine, New York, NY.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kohli, R., Klein, R.S., Schoenbaum, E.E. et al. Aging and HIV Infection. JURH 83, 31–42 (2006). https://doi.org/10.1007/s11524-005-9005-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11524-005-9005-6

Keywords

Search

Navigation